Cingulate Inc. (CING) vs PDS Biotechnology Corporation (PDSB)
A side-by-side comparison of Cingulate Inc. and PDS Biotechnology Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CING
Cingulate Inc.
$4.75HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
PDSB
PDS Biotechnology Corporation
$1.20HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — CING vs PDSB
growth of $100 · dividends reinvested · last 5yCING -99.6% (-66.1%/yr)PDSB -85.7% (-32.3%/yr)PDSB compounded faster over this window
Log scale — wide-divergence pair
CING PDSB
CING vs PDSB: by the numbers
- •PDSB is the larger company ($67M vs $64M market cap).
Metrics side by side
Valuation
| Metric | CING | PDSB |
|---|---|---|
| P/B ratio | 2.73 | N/A |
| EV / EBITDA | 0.21 | N/A |
Profitability
| Metric | CING | PDSB |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -122.71% | N/A |
| ROIC | -83.74% | -3699.99% |
Growth (annualized)
| Metric | CING | PDSB |
|---|---|---|
| Total return CAGR (5Y) | N/A | -39.13% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.